Mesoblast has treated dozen of COVID-19 patients with its remestemcel-L drug

Phase 3 trial testing on severely ill COVID-19 patients has reached 50 per cent enrolment Mesoblast expects to complete enrolment … Read More

The post Mesoblast has treated dozen of COVID-19 patients with its remestemcel-L drug appeared first on Stockhead.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *